A $1.5 Billion Price on Accounts, Not Formulas

What is the signal?

Galderma announced on 14 October 2026 that it had signed an agreement to acquire 100% of ZO Skin Health at an enterprise value of $1.5 billion. The transaction is all cash, subject to customary adjustments, and funded from existing cash reserves and bank debt. The sellers are ZO's shareholders, including funds managed by Blackstone Tactical Opportunities and the Obagi family. Reuters reported the deal a day earlier, on 13 October, and the company's own announcement confirmed it the following day.

The figures on ZO's side read as follows. Net sales of approximately $330 million for the twelve months to June 2026, more than 40 products, manufactured in the United States. Sales reach more than 16,500 physician, medical spa and online accounts across more than 40 countries, supported by a dedicated salesforce and education team. Galderma described ZO's daily regimen range as complementing its existing Alastin peri-procedure range.

Figures for the channel itself arrived in the same period. According to Kline + Company's mid-year 2026 update, the U.S. medical care provider channel grew 6% in the first half of 2026 while Canada declined 1%. For comparison, the equivalent first-half growth rates were 3% in 2025 and 8% in 2024. The same update noted that SkinCeuticals, ZO Skin Health and SkinBetter Science continued to command a significant share of U.S. medical care provider sales, while smaller brands such as Hydrinity, Epicutis and Plated Skin Science posted particularly strong momentum.

Let me set the reading scope first. The transaction has not closed. Galderma said it expects closing in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and other customary closing conditions. The $330 million figure covers the twelve months to June 2026, not a fiscal year. Kline's figures are a mid-year update limited to the North American (U.S. and Canada) medical care provider channel, and brand-level growth rates are not in the published material. So this article treats only the disclosed deal terms and the channel-level numbers as settled, and uses no brand rankings or share figures.

The development reading still points one way. What was priced in this channel was not the list of products but the path by which a product reaches the patient or client.

1. The $1.5 billion did not buy 40 formulas

Place the two disclosed numbers side by side and the structure shows. Dividing the $1.5 billion enterprise value by $330 million in trailing twelve-month sales gives roughly 4.5 times. That is a simple division of two figures from the same announcement, and no profitability multiple was disclosed, so it is no basis for judging the price high or low. What is clear is that this multiple was not placed on the formulas behind 40 products. Recreating 40 formulas costs an order of magnitude less than this.

Three items appear in the same announcement separately from the products: more than 16,500 accounts, a dedicated salesforce, and an education team. Dividing sales by the account count gives roughly $20,000 per account per year. That too is a simple division of two disclosed figures, and account sizes vary, so the average means little on its own — but it does show that revenue here accumulates across many small accounts rather than a handful of large ones.

What this structure means for a brand is not simple. Revenue built on many small accounts is not created by advertising; it is created by account-level visits, education and reorder management. So a brief aimed at this channel needs a field beside the product specification: who explains this product and hands it over. If that field is empty, a good formula still does not enter the channel.

And that field usually cannot be filled alone. Building education materials and a dedicated team from scratch is a different kind of investment from product development. The realistic choice is to decide at the planning stage in what form you will work with someone who already has that organisation.

• Whether the brief has a "who explains and hands it over" field beside the specification
• Whether the account unit — clinic, medical spa or online — is written down
• Whether you decided who creates and who delivers the education material
• Whether an assumed reorder cycle per account is reflected in volume planning

2. Products in this channel fall into two slots

The most operationally useful sentence in Galderma's announcement is the one about complementarity: ZO's daily regimen range complements Alastin's peri-procedure range. That is why one company keeps two brands in the same channel. Inside a clinic, a product occupies one of two slots.

The two slots carry different design conditions. A peri-procedure product assumes a barrier temporarily weakened by a laser or peel, so it leans toward reducing irritants, and its timing and duration are tied to the procedure schedule. A daily regimen product assumes months of continuous use, so sensory comfort, fragrance, size and price sustainability become the deciding criteria. The same ingredient moves in different directions of concentration and texture depending on which slot it enters.

Packaging and use instructions diverge too. A peri-procedure product carries directions like "on day three, twice", while a daily product has to be designed not to collide with other products inside a morning and evening sequence. Make one product serve both slots and the instructions grow longer — and a product with long instructions becomes hard for an account to explain.

So a brief for this channel has to settle not on "a good product" but on "which slot". Settle the slot and concentration, fragrance, size and instructions narrow almost automatically. Leave it open and you get a product that is explained in neither slot.

• Whether the first line of the brief states peri-procedure or daily regimen
• If peri-procedure, which procedure and which day after it the product is used
• If daily, where it sits in the morning and evening sequence
• Whether serving both slots made the use instructions longer

3. The channel grew 6%; e-commerce grew double digits

Kline's figures contain two paths moving at different speeds. The U.S. medical care provider channel grew 6% in the first half of 2026, while U.S. e-commerce grew at a strong double-digit rate over the same period, outpacing the provider channel. The same update noted that ZO Skin Health is preparing an e-commerce relaunch focused on education, regimen guidance and consumer recruitment.

These two paths can take from each other. If a consumer buys online, more cheaply, a product the account used to sell by explaining it, the account has less reason to explain it. So e-commerce in this channel is designed to substitute for the explanation rather than to lower the price. That the relaunch is described as focused on education and regimen guidance reads as that signal.

Where this reaches development is the unit of the product. A product sold as a regimen is not planned one at a time but as a sequenced set. Cleansing, hydration, actives and sun protection have to be divided so their roles do not overlap, and matching sizes so they run out over the same period keeps reordering simple. If one product empties first, the consumer buys that one product somewhere else.

Read the nature of the growth rate as well. 6% in the first half is above 3% in 2025 and below 8% in 2024. So this channel reads as a steady phase rather than a rapid-expansion one, and Canada declined 1% over the same period. North America is not moving in one direction, so an entry plan built around "North America" as a single block will not match the numbers.

• Whether the product was planned as a single SKU or as a sequenced regimen
• Whether sizes within the regimen were matched to deplete over the same period
• Whether the roles of online and account sales were divided in advance
• Whether the U.S. and Canada were kept out of one combined plan

4. What the fast-growing smaller brands have in common

The same update singled out Hydrinity, Epicutis and Plated Skin Science as the smaller brands with particularly strong momentum. Kline attributed that movement to four areas of interest: regenerative ingredients, procedure-adjacent products, microbiome support, and simplified regimens.

Translated into development conditions, the four group into two pairs. The first two are about what goes in; the last two are about how many steps the user is given. It is worth noting that smaller brands establishing themselves alongside large ones usually work the second pair. Competing head-on with a large brand on ingredients costs more than cutting steps to build a set an account can explain easily.

A simplified regimen does not mean making fewer products. To cut a step, one product has to perform two roles reliably, so formulation difficulty rises instead. Combining hydration and actives in one product means re-balancing viscosity, absorption and irritation, and the stability testing list grows. What has to be written next to "reduce to three steps" in a brief is the testing that this adds.

The ingredient side needs more care in wording. Regenerative and microbiome are words that describe a mechanism, and the moment they cross over into an efficacy claim for the finished product, the level of evidence changes. Do not carry raw-material research across as a finished-product effect; writing beside each claim whether its evidence came from raw-material or finished-product testing is the safer habit.

• Whether the design competes by cutting steps or by differentiating ingredients
• Whether the testing added by cutting steps is reflected in schedule and cost
• Whether each claim notes raw-material or finished-product evidence
• Whether a mechanism description was carried over as an efficacy claim

5. The conditions written outside the formula

A few items in Galderma's announcement appear separately although they are not product descriptions: that ZO's products are manufactured in the United States, that it holds a dedicated salesforce and education team, and that it reaches more than 16,500 accounts across more than 40 countries. None of these is stated as a regulatory requirement, but together they show which items get counted as transaction value in this channel.

The manufacturing-origin item is more accurately turned into a question than asserted as a condition. If you are targeting this channel, first confirm whether origin comes up in account conversations and, if so, in what context. Putting origin into a claim without confirming that makes it an unsupported assertion; conversely, if origin does function as a commercial condition in that channel, it becomes an item to settle before the formula.

The education item is clearer. A product sold because an account explains it needs that explanation to exist as a document — use sequence, relation to the procedure schedule, expected initial reactions and how to handle them, and adjustments when it overlaps with other products. This document is a different kind of material from marketing copy, and starting it after the product is finished leaves it out of step with the product. Starting it at the same time the formula is signed off is the right order.

The figure of 40 countries is worth one more read. It means the same product ships to clinics in many markets, and labelling requirements and ingredient restrictions differ by market. If a product is aimed at several countries from the start, choose at the planning stage between setting the formula against the narrowest restriction and splitting the formula by market. Postpone it and one product's formula splits into several.

• Whether you confirmed that origin is an item raised in the target channel
• Whether an unconfirmed origin claim was kept out of the copy
• Whether the account-facing explanation document began at formula sign-off
• Whether you chose between the narrowest restriction and per-market formulas

The first question for the brief

Instead of writing "medical-grade skincare", try adding one more line: is this product in the peri-procedure slot or the daily regimen slot? Those two slots are why Galderma keeps two brands in one channel, and settling the slot narrows concentration, fragrance, size and instructions with it. Leave the slot blank and the product is explained in neither.

The second thing to write is the delivery path. Next to the specification field, write who explains this product and hands it over. In this transaction, the items recorded separately from the product list were the account count and the salesforce and education teams. If that field is empty, the product does not enter the channel regardless of how complete the formula is.

The last is the unit of the set. Write down whether this is a single SKU or a sequenced regimen, and if it is a regimen, whether the products deplete over the same period. Reordering in this channel happens by regimen rather than by product, and one mismatched size breaks the set.